Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients

Transplantation Proceedings

Volumn 44, Issue 1, 2012, Pages 109-114

  Cho, J H ^a   Yoon, Y D ^a   Park, J Y ^a   Song, E J ^a   Choi, J Y ^a   Yoon, S H ^a   Park, S H ^a   Kim, Y L ^a   Kim, C D ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ALLELE; CONFERENCE PAPER; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HAPLOTYPE; HUMAN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHI-SQUARE DISTRIBUTION; CYTOCHROME P-450 CYP3A; DRUG MONITORING; FEMALE; GENE FREQUENCY; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LINEAR MODELS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; REPUBLIC OF KOREA; RISK ASSESSMENT; RISK FACTORS; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863357335     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.11.004     Document Type: Conference Paper

References (21)

1. M.R. First Tacrolimus based immunosuppression J Nephrol 17 suppl 8 2004 S25
2. C.R. Felipe, H.T. Silva, P.G. Machado The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring Clin Transplant 16 2002 262
3. K. Iwasaki Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics Drug Metab Pharmacokinet 22 2007 328
4. P. Kuehl, J. Zhang, Y. Lin Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 2001 383
5. A. Westlind, L. Lofberg, N. Tindberg Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region Biochem Biophys Res Commun 259 1999 201
6. K. Saito, S. Miyake, H. Moriya Detection of the four sequence variations of MDR1 gene using TaqMan MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects Clin Biochem 36 2003 511
7. N.N. Salama, Z. Yang, T. Bui MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells J Pharm Sci 95 2006 2293
8. I.A. Hauser, E. Schaeffeler, S. Gauer ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation J Am Soc Nephrol 16 2005 1501
9. I.A. Macphee, S. Fredericks, M. Mohamed Tacrolimus pharmacogenetics: the CYP3A5 (*)1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians Transplantation 79 2005 499
10. S.I. Min, S.Y. Kim, S.H. Ahn CYP3A5 (*)1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients Transplantation 90 2010 1394
11. J.H. Choi, Y.J. Lee, S.B. Jang Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects Br J Clin Pharmacol 64 2007 185
12. M.D. Floyd, G. Gervasini, A.L. Masica Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women Pharmacogenetics 13 2003 595
13. E.E. Thompson, H. Kuttab-Boulos, D. Witonsky CYP3A variation and the evolution of salt-sensitivity variants Am J Hum Genet 75 2004 1059
14. J.H. Choi, Y.J. Lee, S.B. Jang Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects Br J Clin Pharmacol 64 2007 185
15. I.A. Macphee, S. Fredericks, T. Tai Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement Transplantation 74 2002 1486
16. R.B. Kim MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences Pharmacogenetics 12 2002 425
17. I.A. MacPhee, S. Fredericks, T. Tai The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation Am J Transplant 4 2004 914
18. D.A. Hesselink, R.H. van Schaik, M. van Agteren CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients Pharmacogenet Genomics 18 2008 339
19. D.R. Kuypers, H. de Jonge, M. Naesens CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients Clin Pharmacol Ther 82 2007 711
20. S. Satoh, M. Saito, T. Inoue CYP3A5 (*)1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients Eur J Clin Pharmacol 65 2009 473
21. Y. Dai, M.F. Hebert, N. Isoherranen Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro Drug Metab Dispos 34 2006 836